Overview
PlaqueTec is a precision medicine company pioneering biomarker-based strategies for coronary artery disease (CAD), the leading cause of death worldwide. The company has developed the Liquid Biopsy System (LBS), a specialized catheter that collects blood samples containing biomolecules from coronary plaque at multiple sites simultaneously. PlaqueTec collaborates with research institutions and drug discovery partners to identify endotype-specific biomarkers and advance personalized treatment approaches for CAD.
Frequently asked questions
- What is the PlaqueTec Liquid Biopsy System and how does it work?
- The PlaqueTec Liquid Biopsy System (LBS) is a specialized catheter designed to quickly and reliably collect blood samples containing biomolecules localizing at or being released by coronary plaque. The system samples from the boundary layer at four sites simultaneously, enabling detection of predictive intracoronary artery biomarkers.
- What therapeutic area does PlaqueTec focus on?
- PlaqueTec focuses exclusively on coronary artery disease (CAD), developing precision medicine strategies for prevention, diagnosis, and treatment. The company is dedicated to advancing the understanding of CAD through biomarker identification and endotyping approaches.
- What collaborations has PlaqueTec established?
- PlaqueTec has collaborated with the Babraham Institute on blood screening and flow cytometry analysis to improve CAD treatment, and with RxCelerate on early-phase drug discovery to assess small molecules targeting PlaqueTec-identified biomarkers in cell-based assays.